Trovagene (TROV) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cantor Fitzgerald Upgrades TrovaGene (TROV) to Buy
August 8, 2016 7:28 AM EDTCantor Fitzgerald upgraded TrovaGene (NASDAQ: TROV) from Hold to Buy with a price target of $7.00 (from $5.00).
For an analyst ratings summary and ratings history on TrovaGene click here. For more ratings news on TrovaGene click here.
Shares of TrovaGene closed at $5.20 yesterday.
... MorePiper Jaffray Remains Sidelined on Trovagene (TROV) Following 2Q Miss
August 5, 2016 10:04 AM EDTPiper Jaffray maintained a Neutral rating on TrovaGene (NASDAQ: TROV), and cut the price target to $4.00 (from $5.00), following the company's 2Q earnings report. Trovagene reported revenue of $104K, below the Street' ~$270K. Total revenue consisted of royalty revenue of $48K as well as test revenue of $56K.
Analyst William... More
